{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:21:59Z","timestamp":1786990919270,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004599","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ijrobp.2023.03.042","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T21:54:36Z","timestamp":1678830876000},"page":"105-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and\/or Surgery in Stage III Epidermal Growth Factor Receptor\u2013Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study"],"prefix":"10.1016","volume":"117","author":[{"given":"Nir","family":"Peled","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8455-9327","authenticated-orcid":false,"given":"Laila C.","family":"Roisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Levison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Dudnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Chernomordikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Heching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Dudnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoshana","family":"Keren-Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hovav","family":"Nechushtan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Salhab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dov","family":"Hershkovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomo","family":"Tsuriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Hannes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Rotem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Lazarev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Lichtenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inbal S.","family":"Granot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Krayim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Shalata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanay","family":"Krutman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Blumenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Lavrenkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Kian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2023.03.042_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0002","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0003","doi-asserted-by":"crossref","first-page":"506","DOI":"10.21037\/tlcr.2020.03.40","article-title":"Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival","volume":"10","author":"Casal-Mouri\u00f1o","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0004","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0005","doi-asserted-by":"crossref","first-page":"S1378","DOI":"10.1016\/j.annonc.2020.10.349","article-title":"356MO Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence","volume":"31","author":"Tsuboi","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0006","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","article-title":"Preoperative chemotherapy for non-small-cell lung cancer: A systematic review and meta-analysis of individual participant data","volume":"383","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0007","unstructured":"NCCN Guidelines Version 2.2023 Non-Small Cell Lung Cancer https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf. Accessed April 4, 2023."},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-020-06734-3","article-title":"Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: A SEER cancer registry analysis","volume":"20","author":"Hansen","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0009","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: Proposals for revision of the TNM stage groupings in the forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0010","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0011","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0012","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1200\/JCO.2015.64.2322","article-title":"Prospective analysis of oncogenic driver mutations and environmental factors: Japan Molecular Epidemiology for Lung Cancer Study","volume":"34","author":"Kawaguchi","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0013","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2011.36.8456","article-title":"First-SIGNAL: First-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung","volume":"30","author":"Han","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0014","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0015","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/JTO.0000000000000156","article-title":"Meta-analysis of first-line therapies in advanced non\u2013small-cell lung cancer harboring EGFR-activating mutations","volume":"9","author":"Haaland","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0016","doi-asserted-by":"crossref","first-page":"e21826","DOI":"10.1097\/MD.0000000000021826","article-title":"The efficacy and safety of osimertinib in treating nonsmall cell lung cancer: A PRISMA-compliant systematic review and meta-analysis","volume":"99","author":"Liu","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0017","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s11523-017-0519-0","article-title":"Osimertinib: A review in T790M-positive advanced non-small cell lung cancer","volume":"12","author":"Lamb","year":"2017","journal-title":"Target Oncol"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0018","first-page":"vdaa125","article-title":"Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases","volume":"2","author":"Goldstein","year":"2020","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0019","first-page":"vdab188","article-title":"Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: An open-label, 3-arm, phase II pilot study","volume":"4","author":"Peled","year":"2021","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0020","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0021","doi-asserted-by":"crossref","first-page":"S578","DOI":"10.1016\/j.jtho.2019.08.1209","article-title":"P1.14-58 A phase II study to evaluate neoadjuvant osimertinib for surgically resectable, EGFR-mutant non-small cell lung cancer","volume":"14","author":"Rotow","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0022","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non\u2013small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0023","doi-asserted-by":"crossref","first-page":"6229","DOI":"10.1200\/JCO.2009.22.3370","article-title":"Phase II study of preoperative gefitinib in clinical stage I non\u2013small-cell lung cancer","volume":"27","author":"Lara-Guerra","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0024","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1200\/JCO.2011.39.4882","article-title":"Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non\u2013small-cell lung cancer","volume":"30","author":"Schaake","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0025","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.2217\/fon-2021-0549","article-title":"Neoadjuvant osimertinib with\/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA","volume":"17","author":"Tsuboi","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0026","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.lungcan.2023.02.011","article-title":"Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR mutant lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial","volume":"178","author":"Lv","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0027","unstructured":"Broad Institute. Integrative Genomics Viewer. Available at: https:\/\/software.broadinstitute.org\/software\/igv\/. Accessed October 2, 2022."},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0028","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.21037\/jtd-20-1265","article-title":"Does neoadjuvant targeted therapy provide an opportunity for resectable EGFR-mutant lung cancer: A real-world retrospective study","volume":"12","author":"Lv","year":"2020","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100191","article-title":"Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902\/OLCSG0905 phase II study","volume":"6","author":"Hotta","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0030","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0031","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jtho.2021.01.1628","article-title":"Durvalumab for stage III EGFR-mutated NSCLC after definitive chemoradiotherapy","volume":"16","author":"Aredo","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0032","doi-asserted-by":"crossref","first-page":"248","DOI":"10.21037\/jtd.2018.12.97","article-title":"Radical surgical resection after neoadjuvant targeted therapy in non-small cell lung cancer: A single-center retrospective study of 6 cases","volume":"11","author":"Zhang","year":"2019","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0033","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-022-01590-0","article-title":"The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patients","volume":"21","author":"Yang","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.912801","article-title":"Liquid first is \u201csolid\u201d in na\u00efve non-small cell lung cancer patients: Faster turnaround time with high concordance to solid next-generation sequencing","volume":"12","author":"Sehayek","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0036","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.lungcan.2022.01.013","article-title":"Exploitation of treatment induced tumor lysis to enhance the sensitivity of ctDNA analysis: A first-in-human pilot study","volume":"165","author":"Breadner","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijrobp.2023.03.042_bib0037","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.cllc.2020.11.004","article-title":"Osimertinib maintenance after definitive chemoradiation in patients with unresectable EGFR mutation positive stage III non-small-cell lung cancer: LAURA trial in progress","volume":"22","author":"Lu","year":"2021","journal-title":"Clin Lung Cancer"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623002833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623002833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:06:02Z","timestamp":1759745162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301623002833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0360301623002833"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.03.042","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and\/or Surgery in Stage III Epidermal Growth Factor Receptor\u2013Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.03.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}